Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment
By Mark C. Via
Chapter 1
BACKGROUND AND SCIENTIFIC OVERVIEW: ANTIBODIES AND MONOCLONAL ANTIBODIES
1.1. What Is an Antibody?
1.2. What Is a Monoclonal Antibody?
Chapter 2
CURRENT AND EMERGING TECHNOLOGIES: IMPROVING MONOCLONAL ANTIBODY DESIGN AND PRODUCTION
2.1. Key Breakthroughs in the First 30 Years of Monoclonal Antibody Production
Murine-Derived Monoclonal Antibodies
Chimeric Monoclonal Antibodies
Humanized Monoclonal Antibodies
Fully Human Monoclonal Antibodies
Antibody Fragments
Antibody Conjugates
2.2. Monoclonal Antibody Libraries and Display Technologies
Phage Display
Cambridge Antibody Technology
Dyax
Crucell
MorphoSys
Affitech
Biosite
Affimed Therapeutics
XOMA
Ribosome Display
Cambridge Antibody Technology
Discerna
Other Library-Based Technologies
Alexion Antibody Technologies
BioInvent International
MSM Protein Technologies
Vaccinex
Morphotek
2.3. Other Technologies for Designing Monoclonal Antibodies
Techniques for Improving Hybridoma Production
Abeome
New Technologies for Generating Animal-Derived Monoclonal Antibodies
GENOVAC
Epitomics
Humanization Technology
Abmaxis
EvoGenix
AERES Biomedical/Therapeutic Antibody Group
ImmunoGen
KaloBios Pharmaceuticals
PDL BioPharma
Massachusetts Institute of Technology
XOMA
Transgenic Mice
Amgen
Medarex
AVANIR Pharmaceuticals
XTL Biopharmaceuticals
Regeneron Pharmaceuticals
Human Hybridoma Technology
Morphotek
2.4. Alternative Antibody Formats
Antibody Fragments
Genmab
Synthetic Antibodies
Ablynx
Affibody
Domantis
Enzon Pharmaceuticals/Micromet
EvoGenix
Regeneron Pharmaceuticals
Bispecific Antibodies
Elusys Therapeutics
Micromet
TRION Pharma
Affimed Therapeutics
Pharmexa/Affitech
Biotechnol
Other Antibodies that Enhance Effector Function
BioWa
MacroGenics
TolerRx
University of Oslo
InNexus Biotechnology
Xencor
TeGenero
2.5. Antibody Conjugates
Antibody-Radioisotope Conjugates
Affibody
PBL Therapeutics
Triton BioSystems
Antibody-Drug Conjugates
HERMES Biosciences
Celldex Therapeutics
Scancell
Virexx Medical
Antibody-Toxin Conjugates
EvoGenix
2.6. Technologies for Improving Monoclonal Antibody Characteristics
Protein Engineering
Applied Molecular Evolution
EvoGenix
Verenium
Morphotek
MilleGen
PDL BioPharma
PEGylation
Enzon Pharmaceuticals/Nektar Therapeutics
Prolong Pharmaceuticals
Ambrx
Others
Alternatives to PEGylation
Glycosylation
GlycArt Biotechnology
GlycoFi
Glycotope
Neose Technologies
LFB
Alternative Modes of Administration
Altus Pharmaceuticals
Epic Therapeutics
2.7. Technologies for Improving Monoclonal Antibody Production
Increasing Yields in Mammalian Cultures
Transgenic Animals
Transgenic Plants
Chapter 3
MARKETED AND EMERGING MONOCLONAL ANTIBODIES: PRESENT AND FUTURE THERAPEUTICS
3.1. Approved Therapeutic Monoclonal Antibodies
Profiles of Therapeutic Monoclonal Antibodies Approved for Marketing
Orthoclone OKT3 (Muromonab-CD3) (1986)
ReoPro (Abciximab) (1994)
Rituxan (Rituximab) (1997)
Zenapax (Daclizumab) (1997)
Simulect (Basiliximab) (1998)
Synagis (Palivizumab) (1998)
Remicade (Infliximab) (1998)
Herceptin (Trastuzumab) (1998)
Mylotarg (Gemtuzumab Ozogamicin) (2000)
Campath (Alemtuzumab) (2001)
Zevalin (Ibritumomab Tiuxetan) (2002)
Humira (Adalimumab) (2002)
Xolair (Omalizumab) (2003)
Bexxar (Tositumomab) (2003)
Raptiva (Efalizumab) (2003)
Erbitux (Cetuximab) (2004)
Avastin (Bevacizumab) (2004)
Tysabri (Natalizumab) (2006)
Lucentis (Ranibizumab) (2006)
Vectibix (Panitumumab) (2006)
Soliris (Eculizumab) (2007)
3.2. Monoclonal Antibodies in Development for Cancer
Unconjugated Monoclonal Antibodies for Cancer
Genmab
Medarex
Biogen Idec
Genentech
Human Genome Sciences
Wilex
Immunomedics
Regeneron Pharmaceuticals
ImClone Systems
Antisoma
Micromet
MedImmune
GPC Biotech
ARIUS Research
AVEO Pharmaceuticals
Lpath
Northwest Biotherapeutics
Anti-idiotype Antibodies for Cancer
Menarini Group
Onyvax
Conjugated Monoclonal Antibodies for Cancer
Viventia Biotech
Amgen
Active Biotech
Antisoma
ImmunoGen
Immunomedics
Cambridge Antibody Technology
Seattle Genetics
Merck Serono
CuraGen
Celldex Therapeutics
3.3. Monoclonal Antibodies in Development for Immunological Diseases
UCB
Regeneron Pharmaceuticals
Centocor
Human Genome Sciences
Zymogenetics
Amgen
Biogen Idec/Genentech
Cambridge Antibody Technology
Genmab
MedImmune
Millennium Pharmaceuticals
NovImmune
Medarex
Micromet
BioTie Therapies
CSL
Glenmark Pharmaceuticals
LigoCyte Pharmaceuticals
3.4. Monoclonal Antibodies in Development for Infectious Diseases
NeuTec Pharma
MedImmune
Human Genome Sciences
Progenix Pharmaceuticals
Medarex
XTL Biopharmaceuticals
Elusys Therapeutics
Genmab
AVANIR Pharmaceuticals
3.5. Monoclonal Antibodies in Development for Cardiovascular Diseases
Ablynx
ThromboGenics/BioInvent International
Affimed Therapeutics
Lexicon Pharmaceuticals
3.6. Other Therapeutic Antibodies in Development
Amgen
Elan/Wyeth
Rinat Neuroscience
Wyeth/Cambridge Antibody Technology
Chapter 4
BUSINESS AND STRATEGIC OUTLOOK: MARKET POTENTIAL FOR MONOCLONAL ANTIBODIES AND TRENDS IN THE FIELD
4.1. General Trends
4.2. The Market for Therapeutic Monoclonal Antibodies
Cancer: Solid Tumors
Cancer: Non-Hodgkin's Lymphoma
Immune and Inflammatory Diseases
Transplant Rejection
Rheumatoid Arthritis
Crohn's Disease
Psoriasis
Lupus
Multiple Sclerosis
Asthma
Other Emerging Markets
Age-Related Macular Degeneration
HIV
Alzheimer's Disease
Appendix
CHI INSIGHT PHARMA REPORTS MONOCLONAL ANTIBODIES SURVEY-JULY 2007
References
Company Index with Web Addresses